I-Mab Announces Participation at Jefferies and Piper Conferences in November Nov 6, 2023 08:00AM
Felzartamab Granted Breakthrough Therapy Designation by U.S. Food and Drug Administration (FDA) for Primary Membranous Nephropathy (PMN) Nov 2, 2023 08:00AM
I-Mab Announces Poster Presentations of 4-1BB Bispecific Antibody Portfolio at SITC 2023 Nov 1, 2023 08:00AM
HI-Bio Announces Felzartamab Granted Breakthrough Therapy Designation by U.S. Food and Drug Administration for Primary Membranous Nephropathy (PMN) Oct 31, 2023 04:01PM
I-Mab Announces Phase 1 Data of Givastomig at ESMO 2023 Oct 16, 2023 08:00AM
View Older Stories

Oct 13, 2023 03:12PM HI-Bio to Present at the American Society of Nephrology Kidney Week 2023 Annual Meeting
Oct 10, 2023 08:01AM I-Mab Biopharma (IMAB) and ABL Bio Announce Latest Updates of PD-L1 and 4-1BB Bispecific Antibody TJ-L14B/ABL503
Oct 10, 2023 08:00AM I-Mab and ABL Bio Announce Latest Updates of PD-L1 and 4-1BB Bispecific Antibody TJ-L14B/ABL503
Sep 5, 2023 08:00AM I-Mab Announces Upcoming Participation at September Conferences
Aug 17, 2023 06:00AM I-Mab Provides Mid-Year 2023 Financial Results, Business and Corporate Updates
Jul 5, 2023 08:03AM I-Mab Biopharma (IMAB) Announces Publication of Claudin18.2 x 4-1BB Bispecific Antibody Givastomig
Jul 5, 2023 08:00AM I-Mab Announces Publication of Claudin18.2 x 4-1BB Bispecific Antibody Givastomig in JITC
Jun 22, 2023 08:01AM I-Mab Biopharma (IMAB) Appoints Raj Kannan as CEO
Jun 22, 2023 08:00AM I-Mab Announces the Appointment of Raj Kannan as CEO
May 25, 2023 05:01PM I-Mab Biopharma (IMAB) Announces Encouraging Phase 1b/2 Study Results of Patients with Advanced NSCLC Receiving Uliledlimab and Toripalimab Combination Therapy at ASCO
May 25, 2023 05:01PM I-Mab Announces Encouraging Phase 1b/2 Study Results of Patients with Advanced NSCLC Receiving Uliledlimab and Toripalimab Combination Therapy at ASCO 2023
May 25, 2023 08:00AM HI-Bio Receives FDA Orphan Drug Designation for Felzartamab for the Treatment of Membranous Nephropathy
May 1, 2023 08:00AM I-MAB Filed 2022 Annual Report on Form 20-F
Apr 26, 2023 09:16AM I-Mab Announces Poster Presentation of Proprietary CD73 Antibody Uliledlimab at ASCO 2023
Apr 25, 2023 05:13AM I-Mab Biopharma (IMAB) Announces Positive Outcome in Arbitration Relating to Agreements with Tracon
Apr 25, 2023 01:46AM I-Mab Announces Positive Outcome in Arbitration Relating to Agreements with Tracon
Apr 24, 2023 09:00AM I-Mab Announces First Patient Dosed in Phase 3 Registrational Study of CD47 Antibody Lemzoparlimab in MDS in China
Apr 11, 2023 06:00AM HI-Bio Announces Positive Phase 2 Data on Felzartamab for the Treatment of Primary Membranous Nephropathy
Mar 31, 2023 06:32AM I-Mab Biopharma (IMAB) Provides Business and Corporate Updates, Reports Q4
Mar 31, 2023 06:30AM I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Year Ended December 31, 2022
Mar 20, 2023 08:00AM I-Mab to Report Full Year 2022 Financial Results and Provide Corporate Update on March 31, 2023
Mar 7, 2023 08:02AM MSCI ESG Updated I-Mab to "A" Rating
Nov 3, 2022 09:01AM I-Mab Announces Two Poster Presentations of CD47 Antibody Lemzoparlimab at ASH 2022
Oct 5, 2022 08:00AM I-Mab Announces Poster Presentations of CD47 Antibody Lemzoparlimab and CD73 Antibody Uliledlimab at SITC 2022
Sep 13, 2022 08:02AM I-Mab Biopharma (IMAB) Approved in China to Initiate Phase 3 Registrational Study of Lemzoparlimab in Combination with Azacitidine
Sep 13, 2022 08:00AM I-Mab Announces Approval from China CDE to Initiate Phase 3 Registrational Study of Lemzoparlimab in Combination with Azacitidine in Higher-Risk Myelodysplastic Syndrome
Sep 12, 2022 05:44AM I-Mab Biopharma (IMAB) Reports Positive Phase 2 Data of Lemzoparlimab plus Azacitidine
Sep 10, 2022 09:00AM I-Mab Announces Positive Phase 2 Data of Lemzoparlimab in Combination with Azacitidine (AZA) in Patients with Higher Risk Myelodysplastic Syndrome at ESMO 2022
Sep 6, 2022 08:08AM I-Mab Biopharma (IMAB) to Present Phase 2 Clinical Data of CD47 Antibody Lemzoparlimab at ESMO
Sep 6, 2022 08:00AM I-Mab Announces Oral Presentation of Phase 2 Clinical Data of CD47 Antibody Lemzoparlimab at ESMO Congress 2022
Aug 30, 2022 06:01AM I-Mab Biopharma (IMAB) Provides Business Update, Report H1 22 Results
Aug 30, 2022 06:00AM I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Six Months Ended June 30, 2022
Aug 23, 2022 09:14AM I-Mab Biopharma (IMAB) Announces $40M Insider Buy Plan
Aug 23, 2022 09:13AM I-Mab Announces Share Purchase Plans by the Company and the Senior Management
Aug 19, 2022 09:00AM I-Mab to Report Business and Corporate Updates and Financial Results for the Six Months Ended June 30, 2022 on August 30, 2022
Jul 22, 2022 08:00AM I-Mab Announces First Patient Dosed in Phase 1 Clinical Trial of Claudin 18.2 and 4-1BB Bispecific Antibody TJ-CD4B in Solid Tumors in China
Jul 18, 2022 08:00AM I-Mab to Present Phase 2 Clinical Data of CD47 Antibody Lemzoparlimab at ESMO Congress 2022
Jul 6, 2022 08:00AM I-Mab to Host 2022 R&D Day
Jun 23, 2022 08:00AM I-Mab Receives Top Rankings in Five Categories by Institutional Investor
Jun 15, 2022 08:42AM MorphoSys (MOR) Announces New License Agreements for Felzartamab and TJ210
Jun 15, 2022 08:41AM I-Mab Partner MorphoSys Announces New License Agreements for Felzartamab and TJ210
Jun 14, 2022 04:04PM MorphoSys AG (MOR) and HIBio Enter Into Equity Participation and License Agreements for Felzartamab and MOR210
Jun 14, 2022 04:01PM MorphoSys and HIBio Enter Into Equity Participation and License Agreements for Felzartamab and MOR210
Jun 9, 2022 07:00AM Ferring Announces New Collaboration for Development of Olamkicept
May 31, 2022 08:00AM I-Mab Announces Completion of Patient Enrollment in Phase III Clinical Trial of Eftansomatropin alfa for Treatment of Pediatric Growth Hormone Deficiency
May 26, 2022 05:03PM I-Mab Biopharma (IMAB) Reports Prelim Phase 2 Clinical Data of Uliledlimab
May 26, 2022 05:01PM I-Mab Reports Latest Phase 2 Clinical Data of its Differentiated CD73 Antibody Uliledlimab
May 19, 2022 08:00AM I-Mab to Hold Investor Call to Report Latest Phase 2 Clinical Data of its Differentiated CD73 Antibody Uliledlimab
May 12, 2022 11:39AM AbbVie to Showcase Oncology Portfolio and Pipeline During the 2022 ASCO and EHA Annual Congresses
May 5, 2022 08:00AM I-Mab Provides Updates on Status under Holding Foreign Companies Accountable Act
View Older Stories